Uso de hidrocortisona en la etapa inicial de la neumonía grave de la comunidad

Autores/as

DOI:

https://doi.org/10.55204/scc.v2i2.e42

Palabras clave:

hidrocortisona, neumonía adquirida en la comunidad, tratamiento, efectos adversos

Resumen

Introducción: La neumonía adquirida en la comunidad es un problema que afecta a los sistemas de salud de países desarrollados y subdesarrollados, representa la sexta causa de muerte de forma general y la primera en patologías infecciosas, ubicándose con una mortalidad del 8 al 15% globalmente. La gravedad depende de criterios elaborados por sociedades científicas, las cuales ofrecen los lineamientos para el manejo y la adyuvancia con corticoesteroides sistémicos.

Objetivo: Describir la evidencia actual la cual sustente el beneficio clínico del uso de la hidrocortisona en pacientes con neumonía grave adquirida en la comunidad.

Desarrollo: La terapia complementaria con hidrocortisona mostró ser beneficiosa para ciertos fenotipos con neumonía grave adquirida en la comunidad, se evidencio que reduce la mortalidad, estancia hospitalaria, riesgo de ventilación mecánica o su duración, puede estar asociada a reingreso hospitalario e hiperglucemia, sin embargo, no se vinculó con el aumento de infecciones nosocomiales o hemorragia gastrointestinal.

Conclusión: Es importante como médicos que atendemos a pacientes en estado crítico, encontrar la información proveniente de guías certificadas y avaladas por organismos e instituciones científicas competentes locales e internacionales, para implementar la mejor terapia para pacientes con neumonía grave adquirida en la comunidad.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Kyu HH, Vongpradith A, Sirota SB, Novotney A, Troeger CE, Doxey MC, et al. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022;22(11):1626–47.

Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al. Hydrocortisone in Severe Community- Acquired Pneumonia. New England Journal of Medicine. 2023;388(21):1931–41.

Póvoa P, Nseir S, Salluh J. Severe community-acquired pneumonia: in search of the guiding star. Intensive Care Med. 2023 ;49(6):656-8.

Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):45–67.

Wu JY, Tsai YW, Hsu WH, Liu TH, Huang PY, Chuang MH, et al. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023; 27(1):274.

Instituto Nacional de Estadística y Censos (INEC). Estadísticas Vitales Registro Estadístico de Defunciones [Internet]. ECUADOR; 2021. [Consultado 10 Sept 2023]. Disponible en: https://www.ecuadorencifras.gob.ec/documentos/web- inec/Poblacion_y_Demografia/Defunciones_Generales_2021/Principales_resultados_EDG_2021_v2.pdf

Pitre T, Abdali D, Chaudhuri D, Pastores SM, Nei AM, Annane D, et al. Corticosteroids in Community-Acquired Bacterial Pneumonia: a Systematic Review, Pairwise and Dose-Response Meta-Analysis. J Gen Intern Med. 2023;38(11):2593-606.

Jiang S, Liu T, Hu Y, Li R, Di X, Jin X, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis. Medicine (United States). 2019;98(26).

Guerrero F, Herrera YDC. Protocolo clínico de diagnóstico y tratamiento de pacientes con neumonía adquirida en la comunidad que ingresan a la Unidad de Cuidados Intensivos. Hospital de Especialidades Carlos Andrade Marín Cambios Rev méd. 2021; 20(1):107-116.

Qu J, Zhang J, Chen Y, Huang Y, Xie Y, Zhou M, et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. Emerg Microbes Infect. 2022;11(1):556–66.

Niederman MS, Torres A. Severe community-acquired pneumonia. European Respiratory Review. 2022;31(166).

Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. Chest. 2023;163(3):484–97.

Hong S, Wang H, Liu J, Qiao L. Effects of different doses of methylprednisolone on clinical outcomes in patients with severe community-acquired pneumonia: a study protocol for a randomized controlled trial. Trials. 2022;23(1).

Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg B, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta- analysis. CMAJ. 2020;192(27):755–67.

Chen G, Hu W, Xuan N, Fan H, Zhu J, Cui W, et al. [Survey on the use of glucocorticoids in severe community- acquired pneumonia in intensive care unit of forty-five hospitals in Zhejiang Province]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue [Internet]. 2019 [cited 2023 Sep 9];31(4):488–92. Available from: https://pubmed.ncbi.nlm.nih.gov/31109427/

Vincze I, Czermann R, Nagy Z, Kovács M, Neely M, Farkas R, et al. Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant). J Clin Med. 2022;11(14).

Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021;217:107663.

Ceccato A, Russo A, Barbeta E, Oscanoa P, Tiseo G, Gabarrus A, et al. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. Crit Care. 2021;25(1):432

Dinku H, Amare D, Mulatu S, Abate MD. Predictors of prolonged hospitalization among children aged 2–59 months with severe community-acquired pneumonia in public hospitals of Benishangul-Gumuz Region, Ethiopia: a multicenter retrospective follow-up study. Front Pediatr. 2023; 11:1189155.

Pan J, Bu W, Guo T, Geng Z, Shao M. Development and validation of an in-hospital mortality risk prediction model for patients with severe community-acquired pneumonia in the intensive care unit. BMC Pulm Med. 2023;23(1):303.

Cillóniz C, Dominedò C, Nicolini A, Torres A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms. 2019;7(2):49.

Viasus D, Calatayud L, McBrown MV, Ardanuy C, Carratalà J. Urinary antigen testing in community-acquired pneumonia in adults: an update. Expert Rev Anti Infect Ther. 2019;17(2):107-15.

Karakioulaki M, Stolz D. Biomarkers and clinical scoring systems in community-acquired pneumonia. Ann Thorac Med. 2019;14(3):165-72.

Torres A, Chalmers JD, De la Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, Niederman M, Wunderink RG. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019;45(2):159-71.

Espinoza R, Silva JRLE, Bergmann A, de Oliveira Melo U, Calil FE, Santos RC, Salluh JIF. Factors associated with mortality in severe community-acquired pneumonia: A multicenter cohort study. J Crit Care. 2019;50:82-6.

Instituto Nacional de Estadística y Censos. Registro Estadístico de Camas y Egresos Hospitalarios [Internet]. ECUADOR; 2022. [Consultado 10 Sept 2023]. Disponible en: https://www.ecuadorencifras.gob.ec/documentos/webinec/Estadisticas_Sociales/Camas_Egresos_Hospitalarios/Cam_Egre_Hos_2022/Presentacion_ECEH_2022.pdf

Chen L, Han X, Li Y, Zhang C, Xing X. Impact of systemic corticosteroids on the clinical outcomes in patients with severe community-acquired pneumonia: a multi-center retrospective study. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue [Internet]. 2019 [citado el 16 de septiembre de 2023];31(7). Disponible en: https://pubmed.ncbi.nlm.nih.gov/31441402/.

Van Heijl I, Schweitzer VA, Boel CHE, Oosterheert JJ, Huijts SM, Dorigo-Zetsma W, van der Linden PD, Bonten MJM, van Werkhoven CH. Confounding by indication of the safety of de-escalation in community-acquired pneumonia: A simulation study embedded in a prospective cohort. PLoS One. 2019;14(9): e0218062.

Wu X, Sun T, Cai Y, Zhai T, Liu Y, Gu S, Zhou Y, Zhan Q. Clinical characteristics and outcomes of immunocompromised patients with severe community-acquired pneumonia: A single-center retrospective cohort study. Front Public Health. 2023; 11:1070581.

Vásconez L. PROTOCOLO NEUMONIA ADQUIRIDA EN LA COMUNIDAD [Internet]. Ministerio de Salud pública Ecuador; 2023. [Consultado 10 Sept 2023]. Disponible en: https://www.hgdz.gob.ec/wpcontent/uploads/2023/08/protocolo_neumonia_adquirida_en_la_comunidad_-signed-signed-signed-signed- signed.pdf

National Institutte for Health and Care Excellence. Pneumonia in adults: diagnosis and management Clinical guideline [Internet]. 2023 [Consultado 10 Sep 2023]. Disponible en: www.nice.org.uk/guidance/cg191

Sociedad Andaluza de Medicina Intensiva y Unidades Coronarias. Pneumonia Severity Index (PSI) | SAMIUC [Internet]. 2023 [cited 2023 Sep 11]. Available from: https://www.samiuc.es/pneumonia-severity-index-psi/

Sociedad Andaluza de Medicina Intensiva y Unidades Coronarias. Escala de FINE para evaluar Neumonía adquirida en la Comunidad | SAMIUC [Internet]. 2022 [Consultado 2023 Sep 10]. Available from: https://www.samiuc.es/escala-de-fine-para-evaluar-neumonia-adquirida-en-la-comunidad/

Huang J, Guo J, Li H, Huang W, Zhang T. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis. Medicine (Baltimore) [Internet]. 2019 [citado el 16 de septiembre de 2023];98(13): e14636. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30921179/

Olson G, Davis AM. Diagnosis and treatment of adults with community-acquired pneumonia. JAMA [Internet]. 2020 [Consultado 2023 Oct 5];323(9):885. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32027358/

Seagraves T, Gottlieb M. Are corticosteroids beneficial in the treatment of community-acquired pneumonia? Ann Emerg Med [Internet]. 2019 [Consultado 2023 Oct 6];74(1): e1–3. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29937237/

Meduri GU, Shih M-C, Bridges L, Martin TJ, El-Solh A, Seam N, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med [Internet]. 2022 [Consultado 2023 Oct 6];48(8):1009–23. Disponible en: http://dx.doi.org/10.1007/s00134-022-06684-3

Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med [Internet]. 2023;49(6):615–32. Available from: http://dx.doi.org/10.1007/s00134-023-07033-8

Cangemi R, Carnevale R, Cammisotto V, Nocella C, Bartimoccia S, Taliani G, et al. Corticosteroid use, myocardial injury and in‐hospital cardiovascular events in patients with community‐acquired pneumonia. Br J Clin Pharmacol [Internet]. 2022;88(1):155–65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34087003/

Cavallazzi R, Furmanek S, Arnold FW, Beavin LA, Wunderink RG, Niederman MS, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest [Internet]. 2020;158(3):1008–16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32298730/

Descargas

Publicado

2023-10-31

Cómo citar

1.
Chillogallo Ochoa JA, Novillo Cevallos JF. Uso de hidrocortisona en la etapa inicial de la neumonía grave de la comunidad. Salud ConCienc. [Internet]. 31 de octubre de 2023 [citado 13 de diciembre de 2024];2(2):e42. Disponible en: http://saludconciencia.com.ar/index.php/scc/article/view/42

Número

Sección

Artículos de Revisión